Hormonal
Metformin is the first-line oral pharmacological treatment for Type 2 Diabetes Mellitus (T2DM) across all age groups, primarily by activating AMPK to inhibit hepatic gluconeogenesis and sensitizing peripheral tissues to insulin.
Metformin is the standard first-line medication for Type 2 Diabetes. It works by helping your liver produce less sugar and your body use insulin better. It typically lowers blood sugar by 1-2% without causing weight gain. If you have kidney issues, your doctor may adjust the dose or avoid it. Start with a low dose to minimize stomach upset.
Metformin is a biguanide that is the main first-line oral drug of choice in the management of T2DM across all age groups. Metformin activates adenosine monophosphate-activated protein kinase in the liver, causing hepatic uptake of glucose and inhibiting gluconeogenesis... Metformin is shown to delay the progression of T2DM... by decreasing hepatic glucose synthesis (gluconeogenesis) and sensitizing peripheral tissues to insulin
Why this rating
Based on a clinical review citing UKPDS and general consensus, though it is a review paper rather than a primary RCT.
Source
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
Arun Chaudhury et al. · Frontiers in Endocrinology · 2017
DOI 10.3389/fendo.2017.00006
More from this paper
- Lifestyle modifications, including moderate weight loss (approx 7% body weight) and regular exercise (150 min/week moderate intensity), are cost-effective in preventing or delaying the onset of diabetes and improving glycemic control.Strong
- GLP-1 receptor agonists (e.g., Liraglutide, Exenatide) promote weight loss and improve glycemic control by mimicking incretin hormones, delaying gastric emptying, and increasing satiety, making them advantageous for obese T2DM patients.Good
- SGLT2 inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin) lower blood glucose through an insulin-independent mechanism by blocking glucose reabsorption in the kidneys, providing modest weight loss and blood pressure reduction.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →